Spirosure operates in the healthcare technology sector, focusing on the development and commercialization of advanced diagnostic tools for respiratory diseases. The company's flagship product is the Fenom System, a point-of-care breath analyzer that measures Fractional Exhaled Nitric Oxide (FeNO) levels. This technology aids healthcare professionals in accurately assessing airway inflammation, which is crucial for managing chronic pulmonary conditions such as asthma, COPD, cystic fibrosis, and pulmonary hypertension. By providing precise measurements, the Fenom System helps in titrating medications and adjusting treatments to reduce exacerbations, ultimately improving patient outcomes. Spirosure primarily serves healthcare providers, including hospitals and clinics, who require reliable and innovative tools for respiratory disease management. The company generates revenue through the sale of its diagnostic devices and associated services.

Keywords: FeNO, breath analyzer, asthma management, COPD, cystic fibrosis, pulmonary hypertension, airway inflammation, healthcare technology, diagnostic tools, chronic pulmonary diseases.